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Objective. Obesity is a state of chronic inflamma-
tion that is associated with insulin resistance and type 2
diabetes mellitus (DM), as well as an increased risk of
osteoarthritis (OA). This study was undertaken to define
the links between obesity-associated inflammation, insulin
resistance, andOA, by testing the hypotheses that 1) tumor
necrosis factor (TNF) is critical in mediating these patho-
logic changes inOA, and 2) insulin has direct effects on the
synovial joint that are compromised by insulin resistance.
Methods. The effects of TNF and insulin on cata-
bolic gene expression were determined in fibroblast-like
synoviocytes (FLS) isolated from human OA synovium.
Synovial TNF expression and OA progression were exam-
ined in 2 mouse models, high-fat (HF) diet–fed obese mice
with type 2 DM and TNF-knockout mice. Insulin resis-
tance was investigated in synovium from patients with
type 2 DM.
Results. Insulin receptors (IRs) were abundant in
both mouse and human synovial membranes. Human OA
FLS were insulin responsive, as indicated by the dose-
dependent phosphorylation of IRs and Akt. In cultures of
human OA FLS with exogenous TNF, the expression and
release of MMP1, MMP13, and ADAMTS4 by FLS were
markedly increased, whereas after treatment with insulin,
these effects were selectively inhibited by >50%. The ex-
pression of TNF and its abundance in the synovium were
elevated in samples from obese mice with type 2 DM. In
TNF-knockout mice, increases in osteophyte formation
and synovial hyperplasia associated with the HF diet were
blunted. The synovium from OA patients with type 2 DM
contained markedly more macrophages and showed ele-
vated TNF levels as compared to the synovium from OA
patients without diabetes. Moreover, insulin-dependent
phosphorylation of IRs and Akt was blunted in cultures of
OA FLS from patients with type 2 DM.
Conclusion. TNF appears to be involved in mediat-
ing the advanced progression of OA seen in type 2 DM.
While insulin plays a protective, antiinflammatory role in
the synovium, insulin resistance in patients with type 2
DM may impair this protective effect and promote the
progression of OA.
Osteoarthritis (OA), the most common form of
arthritis, is projected to affect more than 67 million
Americans by 2030 (1) and is one of the leading causes of
physical disability (2). Among various risk factors, obesity
is recognized as a major risk factor for OA. Historically,
it has been proposed that increased joint loading associ-
ated with obesity will cause cartilage damage, leading to
OA (3,4). However, the association between obesity and
OA in the non–load-bearing joints suggests that systemic
factors associated with obesity, such as chronic systemic
inflammation or insulin resistance related to the metabol-
ic syndrome, may contribute considerably to the initiation
and progression of OA (5,6).
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Correlations between common parameters of dia-
betes (hyperglycemia, hyperinsulinemia) and OA have
been observed (5–8). Analysis of the data from the US
Third National Health and Nutrition Examination Survey
demonstrated that each component of the metabolic syn-
drome was more prevalent in the OA population (9). Simi-
lar results were derived from the Japanese Research on
Osteoarthritis Against Disability study (10). Karvonen-
Gutierrez et al (11), in a study using the NHANES data,
reported that insulin resistance was a strong risk factor for
osteophyte-defined knee OA, regardless of body mass.
Interestingly, this association was found only in men, sup-
porting a sex-specific difference in the association between
metabolic syndrome factors and OA. Similarly, Eymard
et al (12) found that type 2 diabetes mellitus (DM) was a
predictor of joint space narrowing only in men with knee
OA. The Netherlands Epidemiology of Obesity study dem-
onstrated that several parameters of obesity were associat-
ed with handOA, but visceral adipose tissue was associated
with OA in men only (13). Although the cause of these
between-sex differences is currently unknown, it has been
suggested that the contributing factors may include an
increased prevalence of distal neuropathy and greater vis-
ceral adiposity in men. Moreover, being overweight in
childhood may predispose men to knee pain in adulthood
(14). Interestingly, a 10% decrease in body weight is associ-
ated with a 50% decrease in the risk of symptomatic OA
(15). It may not be unrelated that a 10% weight loss also
markedly improves insulin sensitivity in obese, insulin-
resistant patients (16). Despite the scope of the clinical
problem, themechanism by whichmetabolic dysfunction in
obesity impacts the initiation and progression of OA is
under-investigated and as yet unknown.
Using a classic mouse model of obesity-associated
type 2 DM, we recently observed an accelerated progres-
sion of posttraumatic OA in association with high-fat
(HF) diet–induced obesity, glucose intolerance, and insu-
lin resistance in mice (17). This effect was not linked to
increased body weight, but rather was associated with the
altered metabolic state resulting from the HF diet and the
development of type 2 DM (17). HF diet–fed mice dis-
played loss of cartilage thickness, larger osteophytes, and
hyperplastic synovium, and therefore these findings could
establish a critical link between metabolic dysfunction
and OA initiation and progression following joint trauma.
Equally important, HF diet–fed mice presented
early OA changes in the uninjured knee joint, including
formation of osteophytes adjacent and proximal to the
hyperplastic synovium. These changes in the uninjured
knees of obese mice with type 2 DM are a possible tissue
response to the systemic factors associated with the meta-
bolic dysfunction. Recently, Gierman et al (18) reported
that an increase in OA progression inmice being fed anHF
diet showed no correlation with increased body weight.
Griffin et al (19) also recently reported that increased joint
loading could not explain the observed increase in incidence
of OA in mice receiving an HF diet. Brunner et al (20) sug-
gested that high dietary fat, independent of weight and asso-
ciatedmechanical stress, appeared to be a risk factor for the
development of OA in a rabbit model. These studies sup-
port the hypothesis that metabolic dysfunction and inflam-
mation both make a critical contribution to increased OA
progression inHF diet–associated obesity and type 2DM.
Although the pathogenesis of OA is not fully
understood, some aspects of the molecular mechanism of
cartilage breakdown are generally accepted. Degradation
of type II collagen and proteoglycan, the main components
of the cartilage extracellular matrix, is mediated by collage-
nases and aggrecanases secreted by both synoviocytes and
chondrocytes (2). The expression of these proteinases
is up-regulated by proinflammatory cytokines such as
interleukin-1b (IL-1b) and tumor necrosis factor (TNF)
(21,22). Importantly, it is established that obesity/type 2
DM is a state of chronic inflammation, with the metabolic
dysfunction of this condition being caused, in part, by the
presence of inflammation, and with TNF playing a major
role (23,24). Thus, in the present study, we tested the
hypothesis that obesity/type 2 DM is an inducer of OA via
the effects of TNF-associated inflammation on fibroblast-
like synoviocytes (FLS). The findings indicated that TNF
contributes to HF diet–associated OA progression in mice,
and that human OA FLS are target cells of insulin, with
insulin playing a protective role in the joint by, at least in
part, suppressing the TNF-induced expression of OA-
associated cartilage catabolic genes. Consistent with this,
we discovered insulin resistance in the synovium from OA
patients with type 2 DM, providing the first evidence of a
clinical connection between synovial insulin resistance and
joint degeneration. These results support the novel con-
cept that the development of OA in individuals with obesi-
ty/type 2 DM is a distinct pathophysiologic process that is
driven by TNF and synovial insulin resistance.
MATERIALS AND METHODS
Clinical samples. All human tissue samples were
obtained following each subject’s provision of written informed
consent, and all experimental studies with human tissue were
performed using a protocol approved by the Institutional Review
Board of the University of Rochester. For isolation of human
FLS, synovial tissue samples were obtained from 4 OA patients
without diabetes (2 men and 2 women, ages 56–87 years) who
had been diagnosed as having OA and had undergone total knee
arthroplasty. The mean6 SD body mass index (BMI) of these
subjects was 31.86 4.1 kg/m2 (range 27.8–37.7), and the fasting
glucose level was 87.86 11.0 mg/dl (range 72–97).
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For analyses of insulin signaling, synovial biopsy tissue
was obtained at the time of arthroplasty from 7 OA patients with
type 2 DM (3 men and 4 women; mean6SD age 63.36 5.8
years, range 52–76 years) and 6 OA patients without diabetes (1
man and 5 women; mean6 SD age 62.36 7.7 years, range 49–84
years). In OA patients with type 2 DM, the mean6SD glycosy-
lated hemoglobin (HbA1c) level was 6.66 0.4% (range 5.8–
7.0%) and the mean6 SD BMI was 33.66 4.5 kg/m2. In OA
patients without diabetes, the HbA1c level was 5.16 0.3% (range
4.5–5.5%) and the BMI was 32.76 4.9 kg/m2. Four of the 7
patients with type 2 DM were receiving treatment with metfor-
min at the time of surgery, with 1 of these patients taking more
than one drug (liraglutide and glimepiride).
Animals. Diet. All handling of the mice and associated
experimental animal procedures were reviewed and approved
by the Committee on Animal Resources of the University of
Rochester. Male C57BL/6J mice and TNF-knockout mice
(B6;129S-Tnf tm1Gkl/J), all purchased from The Jackson Labora-
tory, were housed (5 mice per micro-isolator cage) in a room on
a 12-hour light/dark cycle. The mice, at age 5 weeks, were placed
on either an HF diet (60% kcal, D12492) or a low-fat diet as
control (10% kcal, D12450B) (Open Source Diets; Research
Diets Inc.). Knee OA phenotypes were evaluated in the mice
after administration of the diet for 24 weeks.
Metabolic characterization. Mice were placed on a fast-
ing regimen for 6 hours and then anesthetized with 5% isoflur-
ane, and the body weight was measured. To obtain baseline
glucose levels, tail-vein blood was sampled using a commercially
available glucometer (One Touch Ultra; Lifescan). Following
administration of a glucose bolus (300 mg/kg intraperitoneally),
glucose levels were measured immediately postinjection and at
15, 30, 60, 90, and 120 minutes postinjection, with isoflurane used
at each time point to provide anesthesia for each blood sampling.
To quantify the metabolic status, the net area under the curve
was calculated using GraphPad Prism software (version 4), based
on the curve of glucose levels on the glucose tolerance test in
each mouse.
Immunohistochemistry. For immunohistochemical ana-
lyses of human and mouse synovial tissue, an avidin–biotin–
peroxidase system (Vector) was used, as described previously (22),
to detect 2 primary antibodies: an anti–insulin receptor (anti-IR)
rabbit polyclonal antibody and anti-TNF goat polyclonal antibody
(sc-711 and sc-13550, respectively; Santa Cruz Biotechnology).
Reactions were visualized using diaminobenzidine (Vector) as
substrate. Tissue sections were counterstained with hematoxylin.
Immunofluorescence analysis. Two primary antibod-
ies, an anti-CD14 rabbit monoclonal antibody (ab183322; Abcam)
and anti-CD68 mouse monoclonal antibody (GTX73723; Gene-
Tex), were used to detect monocytes and macrophages in human
synovial tissue. Fluorescent Cy3-conjugated AffiniPure donkey
anti-rabbit IgG (heavy and light chains) and fluorescein isothiocy-
anate–conjugated AffiniPure donkey anti-mouse IgG (heavy and
light chains) (711-165-152 and 715-095-150, respectively; Jackson
ImmunoResearch) were used to detect the primary antibodies.
Sections were then mounted with ProLong Gold antifade reagent
withDAPI (P3691; Life Technologies) for detection of monocytes
andmacrophages by fluorescencemicroscopy.
Immunoprecipitation and Western blot analysis. Cell
protein lysates were harvested from synovial tissue samples, and
IRs were immunoprecipitated with anti-IRb (sc-711; Santa Cruz
Biotechnology) as previously described (25). Phosphorylation of
the immunoprecipitated IRs was assessed by Western blotting
using an antibody against IRb phosphotyrosine (05-321; EMD
Millipore). In addition, direct tissue lysates were assessed by
Western blotting for phosphorylation of IRb (3024; Cell Signal-
ing Technology), IRb subunit (sc-711; Santa Cruz Biotechnolo-
gy), the Ser473-phosphorylated form of Akt (4060; Cell Signaling
Technology), and total Akt (9272; Cell Signaling Technology).
Harvesting of mouse tissue and histologic analysis of
OA progression. The isolation and processing of mouse knees
for histologic analysis were performed as described previously
(17). Each diet group contained 5–8 mice per group. For histo-
morphometric analyses, 3 sagittal sections from the knee joints
of mice in each diet group were stained with Alcian blue and
hematoxylin. Osteophytes were measured using OsteoMeasure
software (OsteoMetrics). Histologic scores of the synovial tissue
from each section were also obtained, with the score represent-
ing the degree of synovial hyperplasia (i.e., thickness and cellu-
larity of the synovial membrane). A subjective scoring system of
0–2 was used, in which 05 a synovial lining that is several (2–3)
cell layers thick or,10 mm thick (normal), 15 synovial thicken-
ing with a lining cell layer between 5 and 10 cells thick or
between 10 mm and 20 mm thick, and 25 severe thickening of
the synovial lining with a lining cell layer .10 cells thick and/or
.20 mm thick. Results were normalized to the values in low-fat
diet–fed lean control mice (set at 1.0). Synovial histologic scor-
ing was performed in a blinded manner by 4 independent
observers (ES, JHS, MJZ, and RAM).
Isolation and culture of human OA FLS. Human syno-
viumwasminced and incubatedwith 1mg/ml of type II collagenase
(Worthington Biochemical) in serum-free, standard Dulbecco’s
modified Eagle’s medium (DMEM; Gibco) containing 1 gm/liter
glucose, for 2 hours at 378C. Isolated cells were filtered through a
70-mm filter, extensively washed, and cultured in DMEM sup-
plemented with 10% fetal bovine serum (Sigma-Aldrich).
Adherent FLS were passaged (at a 1:3 split) at 80–90% conflu-
ency, with cells between passages 4 and 7 used in the experi-
ments. Cells at passage 4 were analyzed by flow cytometry, with
the results showing that the cell population contained ,1%
CD141 or CD1231 monocytes or macrophages, and ,1%
CD451 leukocytes.
Treatment of human OA FLS with proinflammatory
cytokines and insulin. FLS were serum-starved overnight prior
to proinflammatory cytokine and insulin treatments. For the
study of insulin signaling, cells were treated with doses of insulin
between 1 nM and 100 nM (Sigma-Aldrich) for 5 minutes. Cells
were lysed and proteins were isolated by sodium dodecyl sulfate–
polyacrylamide gel electrophoresis for Western blotting. For
the assessment of MMP1 and MMP13 released into the medium,
aliquots of medium for sodium dodecyl sulfate–polyacrylamide gel
electrophoresis were normalized to cell numbers in the dishes from
which the medium was recovered. For analyses of gene expression
following cytokine treatment, the cells were treated for 24 hours
with different concentrations of TNF (0, 1, 3, 10, or 30 ng/ml) and
insulin (0, 1, or 100 nM). At all time points, cell viability was.90%.
Quantitative reverse transcription–polymerase chain
reaction (qRT-PCR). Total RNA was extracted from human
OA FLS using an RNeasy Plus Mini kit (Qiagen). Synovial cap-
sule RNA was isolated according to the method described by
Van Meurs et al (26). Briefly, skeletal muscle was dissected away
from the knee joint of the mouse. The patellar ligament was cut
close to the tibia. This incision was extended both medially and
laterally to join at the posterior of the knee. The incision was
then extended both medially and laterally to join at the top of
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the patellar plate. The triangular wedge of the synovial capsule
was recovered. The patellar plate, patella, and patellar ligament
were dissected and removed, yielding medial and lateral seg-
ments of the synovial capsule. This tissue was homogenized, total
RNA was extracted, and qRT-PCR was performed as described
previously (27). The housekeeping gene used for the mouse stud-
ies was Gapdh, and that used for the human FLS studies was
YWHAZ (encoding 14-3-3 protein z/d).
Analysis of insulin signaling in human synovial biopsy
tissue. Human synovium was harvested from OA patients dur-
ing total knee arthroplasty, from the suprapatellar pouch of the
knee joint adjacent to the femoral articular surface, and the
samples were placed in saline on ice. After fat and scar tissue
were removed, a scalpel was used to scrape and recover the
synovial lining from the surgical sample. This isolated tissue was
then washed in saline and placed in serum-free DMEM at
378C. Insulin was added (1 or 10 nM) for 5 minutes. Samples
were recovered, washed in saline, and added to lysis buffer
(50 mM Tris, 140 mM NaCl, 50 mM NaF, 1% Triton X-100,
10% glycerol, protease inhibitor cocktail [Roche], and 2.0 mM
Na3VO4). Protein content was measured using the Bradford
method (ThermoScience).
Assessment of IR signaling was performed usingWestern
blotting, as described above. Quantitation was performed using
chemiluminescence imaging (ThermoScience) and a ChemiDoc
XRS1 Systemwith Image Lab software (version 5.1; Bio-Rad).
Statistical analysis. All experiments with human FLS
were performed using cell lines generated from 3 different
patient samples, each line being used in 3 separate experiments
and with samples from each experiment assayed in triplicate. In
the mouse experiments and analyses of human synovial tissue
explants, the number of animals or samples used per group var-
ied, and different statistical tests were used (either one-way or
two-way analysis of variance with applicable post hoc tests or t-
tests). For differences between groups and between condition
effects, P values less than 0.05 were considered significant.
RESULTS
Expression of IRs in the synovial membrane. It
is not knownwhether insulin has a direct and physiological-
ly important effect on the synovial joint. Results from
immunohistochemical analysis of the synovial membrane
of mice indicated that IRs were strongly expressed in the
synovium, with detectable expression in mouse articular
chondrocytes as well (Figures 1A andB). Human synovium
obtained from OA patients undergoing total knee arthro-
plasty also displayed strong expression of IRs (Figure 1C).
Treatment of human OA FLS with insulin induced
a dose-dependent increase in IR autophosphorylation, as
well as an increase in the phosphorylation of the central
signaling mediator of insulin action, the serine kinase Akt
(Figure 1D). Importantly, phosphorylation of Akt was
observed following the administration of physiologically
relevant levels of insulin, in doses ranging from 0.1 nM to
1.0 nM.
Regulation of synovial expression of cartilage-
degrading enzymes by insulin. During active OA, FLS
are known to secrete proteases into the synovial fluid that
contribute to the degradation of articular cartilage matrix.
In the case of ADAMTS4, MMP1, and MMP13, their
expression by human OA FLS was relatively low until the
FLS were exposed to the proinflammatory cytokine TNF
(Figure 2). Exogenous TNF at concentrations of 1.0–30 ng/
ml markedly increased the expression of these 3 catabolic
enzymes (Figures 2A–C). It should be noted that we inves-
tigated ADAMTS4, as opposed to ADAMTS5, because, as
reported by others, ADAMTS5 expression in human OA
FLS is not induced by inflammatory cytokines and is the
important homolog inmice, not humans.
When human OA FLS were exposed to 100 nM
insulin, the induction of ADAMTS4, MMP1, and MMP13
expression by TNF was suppressed by ;50% in cells cul-
tured with the lower TNF concentrations (Figures 2A–C).
Insulin had an equally suppressive effect at doses between
1.0 nM and 100 nM (Figures 2D–F). Overall, these data
establish a regulatory role for insulin in modulating the
expression of these critical OA-related catabolic genes in
FLS. Thus, insulin may play a physiologic role in protecting
the articular cartilage by suppressing proinflammatory
Figure 1. Insulin receptors (IRs) are expressed in mouse and
human synovium and are functional in human fibroblast-like syno-
viocytes (FLS). A and B, Immunohistochemical staining demon-
strates abundance of IRs in a representative knee joint section from
a C57BL/6 mouse (A), in contrast to a representative knee joint sec-
tion used as negative control (no primary antibody) (B). Boxed areas
in left panels are displayed at higher magnification in right panels.
Original magnification 3 50 in left panels; 3 200 in right panels. C,
Immunohistochemical staining demonstrates abundant expression of
IRs in human synovium obtained from a patient with osteoarthritis
(OA) undergoing total knee arthroplasty. Original magnification 3
200. D, Isolated human OA FLS were treated without or with insulin
at various concentrations for 5 minutes. IRb autophosphorylation
and phosphorylation of Akt (Ser473) were assessed by Western blot-
ting in immunoprecipitates and lysates, respectively. F5 femur;
T5 tibia; M5meniscus; SM5 synovial membrane.
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cytokine–dependent expression of these cartilage-degrading
enzymes.
Consistent with the gene expression data, TNF
treatment increased the release of MMP1 and MMP13 by
human OA FLS into the culture medium (Figure 2G).
Importantly, insulin suppressed both the basal and the
cytokine-dependent enzyme levels in the culture medium,
with the higher concentration of insulin (100 nM) being the
most effective. The lower efficacy of the 1 nM dose of insu-
lin may reflect a decrease in functional insulin levels in the
medium, due to insulin degradation, over the course of the
24-hour incubation.
Regulation of cytokine and growth factor expres-
sion by insulin. Expression of growth factors, including
bone morphogenetic protein 2 (BMP-2), and proinflam-
matory cytokines, such as TNF, IL-6, and IL-1b, by cells in
the synovial membrane is associated with OA pathologic
changes (28,29). Consistent with this, treatment of human
OA FLS with TNF markedly increased the expression of
BMP2 (Figure 3A), IL6 (Figure 3B), IL1B (Figure 3C),
and TNF (Figure 3D). Of note, TNF induction of its own
transcript was .50-fold (Figure 3D), while induction of
IL1B was less robust (;5-fold) (Figure 3C). The addition
of insulin into these cultures was not effective at inhibiting
the TNF induction of IL1B and TNF (Figures 3C and D),
but it did significantly inhibit the TNF induction of both
BMP2 (Figures 3A and E) and IL6 (Figures 3B and F).
Elevated expression of TNF in the synovium of
HF diet–fed obese mice. Inflammatory cytokines play
an important role in the pathogenesis of rheumatoid arth-
ritis (30), and their role in OA has been primarily impli-
cated in the early inflammatory phase that occurs acutely
Figure 2. Insulin inhibits tumor necrosis factor (TNF)–dependent expression and release of catabolic enzymes in human fibroblast-like synovio-
cytes (FLS) from patients with osteoarthritis (OA). A–F, Human OA FLS were treated without or with TNF at doses of 1–30 ng/ml and insulin
at 100 nM (A–C) or with TNF at 10 ng/ml and insulin at doses of 0–100 nM (D–F) for 24 hours. Cells were harvested, RNA was isolated, and
the expression of ADAMTS4 (A and D), MMP1 (B and E), and MMP13 (C and F) was determined by quantitative reverse transcription–polymer-
ase chain reaction. Results are the mean6SEM of 3 human FLS cell lines in 3 experiments, each assayed in triplicate. Symbols represent gene
expression levels in FLS from individual patients. Data were analyzed by two-way repeated-measures analysis of variance (ANOVA) with Sidak’s
post-test for multiple comparisons (A–C) or by ordinary one-way ANOVA with Dunnett’s post hoc test for multiple comparisons (D–F). G, The
culture medium was recovered from FLS previously treated for 24 hours without or with TNF (1 or 10 ng/ml) and without or with insulin (1.0
or 100 nM). Release of MMP1 and MMP13 into the culture medium was assessed by Western blotting. *5P , 0.05; **5P , 0.01; ***5P ,
0.001; ****5P , 0.0001.
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following injury in posttraumatic OA (31,32). TNF plays
an important role in both obesity and arthritis, and is a
potent promoter of chondrocyte hypertrophy (33). In our
experiments with obese mice, we found that the expres-
sion of Tnfa in synovial capsules from HF diet–fed obese
mice was elevated 6-fold after 20 weeks on the HF diet, as
compared to that in lean control mice after 20 weeks on
the low-fat diet, whereas expression of Il1b was more
modestly elevated in the HF diet–fed obese mice com-
pared to lean controls (Figures 4A and B). Interestingly,
Adamts5 expression was also elevated in the synovium
fromHF diet–fed mice (Figure 4C).
Immunostaining of the mouse synovial membranes
revealed amplified TNF expression in the synovium from
HF diet–fed mice, with the strongest staining for TNF
adjacent to developing osteophytes (Figure 4E). Con-
versely, samples from lean mice showed little immuno-
staining of the synovial membranes for TNF (Figure 4D).
Mediation of both metabolic dysfunction and OA
pathologic changes by TNF in obese mice. To establish a
cause-and-effect relationship between TNF and the patho-
logic changes observed in the knee joints of obese mice, a
loss-of-function approach was taken, in which TNF-
knockout mice were compared to wild-type mice in groups
receiving either a low-fat diet (lean controls) or an HF diet.
Figure 3. Insulin has selective inhibitory effects on inflammatory
cytokine expression in human OA FLS. Human OA FLS were
treated without or with TNF at doses of 1–30 ng/ml and insulin at
100 nM (A–D) or with TNF at 10 ng/ml and insulin at doses of 1–
100 nM (E and F) for 24 hours. Expression of BMP2 (A and E), IL6
(B and F), IL1B (C), and TNFA (D) was determined by quantitative
reverse transcription–polymerase chain reaction. Results are the
mean6 SEM of 3 human FLS cell lines in 3 experiments, each
assayed in triplicate. Symbols represent gene expression levels in
FLS from individual patients. Data were analyzed using two-way
repeated-measures ANOVA with Sidak’s post-test for multiple com-
parisons (A–D) or by ordinary one-way ANOVA with Dunnett’s post
hoc test for multiple comparisons (E and F). *5P , 0.05; **5P ,
0.01; ***5P , 0.001; ****5P , 0.0001. NS5 not significant (see
Figure 2 for other definitions).
Figure 4. Tumor necrosis factor (TNF) expression is amplified in
synovium from obese diabetic mice and is associated with increased
osteophyte formation and synovial hyperplasia. A–C, Synovial cap-
sules from the knees of C57BL/6 mice fed either a low-fat (lean)
diet or a high-fat (HF) diet for 5 months were removed, and RNA
was isolated. Expression of Tnfa (A), Il1b (B), and Adamts5 (C) was
measured by quantitative reverse transcription–polymerase chain
reaction. Results are the mean6 SEM of 6 mice per diet group,
assayed in triplicate, with groups compared by 2-tailed t-test. *5P
, 0.05. D and E, Representative total knee joints from mice in the
lean diet group (D) or the HF diet group (E) were fixed, embedded,
and sectioned, and expression of TNF was determined by immuno-
histochemistry. Matching serial synovial tissue sections were stained
with Alcian blue and hematoxylin. Top, Blue arrow indicates normal
synovium, and red arrows indicate hyperplastic synovium. Boxed
areas in middle panels are displayed at higher magnification in the
bottom panels. Original magnification 3 100 in top and middle pan-
els; 3 400 in bottom panels. OP5osteophyte; F5 femur; T5 tibia;
M5meniscus.
EFFECTS OF INSULIN ON EARLY OA CHANGES 1397
As previously reported (34,35), TNF-knockout mice were
partially resistant to the weight gain associated with the HF
diet (Figure 5A). Similarly, the TNF-knockout mice on the
HF diet displayed less glucose intolerance than did the
wild-type mice on the HF diet (Figures 5B and C). TNF-
knockout lean control mice fed the low-fat diet had a body
weight and glucose tolerance test results that were compa-
rable to those of wild-type control mice on the same diet.
Similar to the findings in our previous report (17),
wild-type mice on the HF diet formed osteophytes that
were larger than those in low-fat diet–fed lean control mice
(Figures D and F), and the joints of HF diet–fed obese
wild-type mice were found to display more synovial hyper-
plasia (Figures 5H and I). Importantly, TNF-knockout
mice on the HF diet were rescued from the formation of
large osteophytes (Figures 5F and G) and showed signifi-
cantly less synovial membrane hyperplasia when compared
to HF diet–fed wild-type mice (Figures 5H and I). These
results indicate a critical role for TNF inmediating theOA-
related changes seen in obesemice.
Impaired insulin signaling in the synovium of
patients with type 2 DM. Similar to previous findings in
the adipose tissue of obese, insulin-resistant patients and
in animal models, the synovium from obese OA patients
with type 2 DM contained markedly increased numbers of
macrophages compared to the synovium fromOA patients
without diabetes, as visualized by fluorescence immunohis-
tochemistry (Figures 6A and B). Consistent with the find-
ings in obese diabetic mice (shown in Figure 4), human
synovium from patients with type 2 DM also had higher
expression levels of TNF compared to synovium from
patients without diabetes (Figures 6C and D).
To examine insulin responsiveness in the human
synovium, synovial biopsy tissue samples from patients with
Figure 5. Ablation of tumor necrosis factor (TNF) blunts high-fat (HF) diet–dependent metabolic dysfunction, osteophyte formation, and synovial
hyperplasia in mice. TNF-knockout (KO) mice and wild-type (WT) control mice were placed on either an HF diet or a low-fat (lean) diet for 3
months. A–C, Body weight (A), glucose levels as determined by the glucose tolerance test (GTT) (B), and area under the GTT curve (AUC) (C) were
assessed at the time of tissue harvesting from mice in each diet group. D–G, Knee joint sections from WT and TNF-knockout mice on either a lean
diet (D and E) or an HF diet (F and G) were assessed for osteophytes by immunostaining with Alcian blue and hematoxylin. Blue arrows denote
synovium. OP5osteophyte; F5 femur; T5 tibia; M5meniscus. Original magnification 3 200. H and I, Osteophyte area (H) and relative synovial his-
tologic score (I) were quantitated in the synovium from mice in each diet group. Results are the mean6 SEM of 5 mice per group, with groups com-
pared by two-way analysis of variance with Bonferroni-Dunn test for multiple comparisons. *5P , 0.05; **5P , 0.01; ***5P , 0.001.
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type 2 DM and patients without diabetes were exposed to
insulin, and IR signaling was examined. Not only was IR
autophosphorylation blunted in samples from patients with
type 2 DM (Figures 6E and F), but also the insulin-induced
phosphorylation of Akt (Ser473) was completely absent in
the synovium from patients with type 2 DM compared to
that from patients without diabetes (Figures 6E and G).
This is the first study to show impaired synovial insulin
responsiveness in patients with type 2 DM, a finding that is
consistent with the insulin resistance in this tissue.
DISCUSSION
We recently reported that progression of posttrau-
matic OA was accelerated in a mouse model of obesity
and type 2 DM (17). Obesity is recognized as a chronic,
systemic proinflammatory state involving the same cyto-
kines that have been implicated in OA (36). Adipose tis-
sue in obese individuals and in animal models contains
increased numbers of activated macrophages that release
proinflammatory cytokines such as IL-1b, TNF, and IL-6
(37). These elevated cytokine levels promote proinflam-
matory changes in adipocytes that, in turn, release addi-
tional proinflammatory mediators and adipokines to
amplify the inflammatory response and act both locally
on adipocytes and systemically to impair insulin action in
insulin target tissues (23,24).
The critical role of TNF in this inflammatory and
dysregulated metabolic state of obesity in mouse models is
well established. In fact, the TNF-knockoutmouse is known
Figure 6. Human synovium from OA patients with type 2 diabetes mellitus (DM) has more abundant macrophages, expresses increased levels of
TNF, and displays blunted insulin responsiveness. A and B, Comparable synovial tissue sections from OA patients without diabetes (A) and OA
patients with type 2 DM (T2D) (B) were assessed by fluorescence immunohistochemistry to identify macrophages (CD681 cells) and monocytes
(CD141 cells). Boxed areas in top panels are displayed at higher magnification in bottom panels. Original magnification 3 50 in top panels; 3 400
in bottom panels. Stained with hematoxylin and eosin (H&E); counterstained with DAPI. C and D, Synovium from OA patients without diabetes
(C) and OA patients with type 2 DM (D) was assessed by immunohistochemistry for TNF expression. Original magnification 3 200. E–G, Addi-
tional synovial tissue samples from OA patients with type 2 DM and those without diabetes were incubated in cell culture medium without or with
insulin (Ins) (1 or 10 nM) for 10 minutes, or in bovine serum albumin (BSA) alone as control. Western blotting was performed to assess the levels
of insulin receptor (IR) autophosphorylation and serine phosphorylation of Akt (Ser473) (representative blots shown) (E). Densitometric scanning
was performed to quantify the levels of IRb phosphorylation (F) and Akt phosphorylation (G). Results are the mean6SEM of 7 patients with
type 2 DM and 6 patients without diabetes. Groups were compared by ordinary one-way ANOVA with Dunnett’s post hoc test for multiple com-
parisons. *5P , 0.05. See Figure 2 for other definitions.
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to be resistant to HF diet–induced insulin resistance and
obesity (34,35), a systemic phenotype that was further con-
firmed herein (Figure 5). Similar conclusions were drawn
from investigations using TNF receptor type I–knockout
mice (38) and antibody blockade of TNF in mouse models
(39,40), as well as in a few clinical studies (41–43).
In this study, we show, for the first time, that the
number of macrophages is markedly increased in the syno-
vium of OA patients with type 2 DM as compared to OA
patients without diabetes (Figure 6). Furthermore, the lev-
els of TNF are also elevated in the synoviumofOApatients
with type 2 DM. The findings from our mouse experiments
provided evidence of a link between the elevated TNF lev-
els in obesity and accelerated OA. Not only were the levels
of TNF chronically elevated in the synovium of obese mice,
but also the obesity-dependent amplification of TNF
expression was greater than that of IL-1b, the other major
proinflammatory cytokine implicated inOA.
The impact of TNF expression in the human syno-
vium was demonstrated by its enhancing effect on the
expression of inflammatory cytokines (IL6) and growth fac-
tors (BMP2) as well as the expression of catabolic enzymes
(MMP1,MMP13, and ADAMTS4) in human OA FLS. All
of these gene products are well-known inducers of chon-
drocyte hypertrophic change, cartilage degeneration, and/
or osteophyte formation (2). In response to exogenous
TNF, we observed a .50-fold increase in Tnfa expression,
and found that this was not inhibited by insulin. Nonethe-
less, this indicates a robust mechanism of feed-forward
amplification in the synovium. This raises the possibility
that a modest increase in synovial TNF levels, originating
from the systemic circulation or the increased population
of macrophages in the synovial membrane, can result in a
marked increase in cytokine expression in synoviocytes.
The hyperglycemia previously observed in HF diet–
fed mice may be one mechanism by which TNF expression
is induced in resident synovial macrophages (17). Although
we have already established the link between systemic loss
of TNF and suppression of OA changes in obese mice, fur-
ther investigations are ongoing to determine the specific
impact of cartilage- and synovium-specific loss of TNF on
OAprogression in obesity.
The blunting of HF diet–induced early osteophyte
formation and its close spatial relationship to hyperplas-
tic synovium in the absence of joint trauma in the
TNF-knockout mouse are direct evidence of the critical
contribution of this cytokine to the enhanced OA pheno-
type seen in obesity. The relationship of synovial hyper-
plasia to OA-related chondropathy has been noted
previously (22,44), with activated synovial macrophages
playing a key role in the inflammatory process (21), lead-
ing to expansion of the lining cell layer with occasional
infiltration by lymphocytes and monocytes (45). These
synovial events had not been previously characterized in
the context of diabetes and/or obesity.
Interestingly, anti-TNF therapy has been proposed
as a candidate treatment strategy for OA (22,46). A recent
study demonstrated that adalimumab, a human anti-TNF
antibody inhibitor, was effective in human knee OA (47).
Nonetheless, the results of multiple clinical studies with
anti-TNF therapies have been conflicting and inconsistent
(48,49).Whether these inconsistencies reflect differences in
study design or patient selection is unclear. A future investi-
gation of anti-TNF therapy restricted to an obese/type
2DMpatient population withOAwould be interesting.
In the present study, we also demonstrated the
expression of IRs in the synovial membrane and a func-
tional IR signaling pathway in human OA FLS. Rosa
and colleagues recently reported that chondrocytes also
express functional IRs that respond to physiologic insu-
lin concentrations (50). Note that our immunohisto-
chemical analysis of IR expression in the knee joints of
mice confirmed the expression of IRs in mouse chondro-
cytes (Figures 1A and B). Moreover, we found that insu-
lin inhibited TNF-dependent expression of ADAMTS4
(Figures 2A and D),MMP1 (Figures 2B and E),MMP13
(Figures 2C and F), and IL6 (Figures 3B and F) by
;50% in human OA FLS. Importantly, insulin also
markedly inhibited the release of MMP1 and MMP13
into the cell culture medium (Figure 2G). These results
suggest that insulin may be cartilage protective by dampen-
ing the potentially cartilage-damaging response to TNF.
Thus, it follows that the classic insulin resistance associated
with obesity and type 2DMwould impair this role of insulin
if the synovium develops insulin resistance, similar to that
found in other insulin target tissues.
Notably, our findings revealed that insulin signaling
in human OA synovium from patients with type 2 DM was
impaired (Figure 6). These analyses of synovial biopsy tis-
sue, rather than isolated FLS, more closely mimic the
microenvironment of the synovium in vivo, and the find-
ings are likely a reflection of the crosstalk between FLS
and mononuclear cells. Taken together, these results sug-
gest a mechanism by which patients with type 2 DM could
develop increased susceptibility to the initiation and pro-
gression of OA.
In this study, we document the key tissue and
molecular phenotypes that occur in OA in conjunction
with obesity and type 2 DM. We show that human OA
FLS are insulin responsive, and that insulin down-
regulates the expression of IL6, possibly the expression of
BMP2, and the expression of cartilage-degrading catabolic
enzymes (aggrecanases and MMPs) in these cells. More-
over, catabolic responses of FLS to TNF are blocked by
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insulin, thereby suggesting the mechanism through which
activation of insulin signaling may prevent a pathologic
cascade of catabolic change in the joint whenever systemic
or local TNF levels are transiently raised. Furthermore, we
demonstrate that in obesity/type 2 DM, there is increased
macrophage infiltration into the synovium that coincides
with the increase in synovial TNF expression and the
development of synovial insulin resistance.
Overall, based on the results reported herein, we
propose the novel idea that the development and progres-
sion of OA in conjunction with obesity/type 2 DM is a
unique pathologic process. We provide evidence that this
process may involve elevated numbers of macrophages in
the synovium, increased synovial TNF expression, devel-
opment of synovial insulin resistance, and the loss of the
protective role of insulin in the synovium and in the joint.
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